Circulating monocytes and B-lymphocytes in neovascular age-related macular degeneration

Figures & data

Figure 1 Gating strategies for monocytes and subgroups.

Notes: (a) Nonclassical monocytes; (b) intermediate monocytes; (c) classical monocytes.

Table 1 Population characteristics

Characteristics	Patients with AMD (n=31)	Control individuals (n=30)	P-value
Age, years, mean (SD)	79.7 (6.0)	77.2 (6.5)	0.131§
Males, n (%)	10 (32)	16 (53)	0.096#
BMI, kg/m^2, mean (SD)	26.6 (5.1)	25.9 (4.6)	0.555§
Previous smoker, n (%)	16 (52)	16 (53)	0.893#
Excessive alcohol use, n (%)	7 (23)	8 (27)	0.711#
Physically active, n (%)	9 (29)	7 (23)	0.613#
CRP level, mg/L, n (%)†			0.270#
<3.1	20 (67)	24 (83)
3.1–8.0	8 (27)	3 (10)
>8.0	2 (7)	2 (7)
White blood cells, in ×10^9 cells/L, mean (SD)‡	6.4 (1.6)	6.1 (1.3)	0.430§

Notes:

§ Independent samples t-test;

# χ² test;

† data missing for one patient with AMD and one control individual;

‡ data missing for one patient with AMD and three control individuals.

Abbreviations: AMD, age-related macular degeneration; BMI, body mass index; CRP, C-reactive protein.

Table 2 Total monocytes and subpopulation distribution of monocytes, expressed as percentage (interquartile range)

Population of cells	Patients with AMD	Control individuals	P-value§
Total monocytes†	5.5 (4.3–6.5)	6.5 (5.3–7.3)	0.028
Classical monocytes‡	68.5 (60.8–71.1)	69.4 (66.8–75.9)	0.509
Intermediate monocytes‡	5.1 (3.1–7.2)	5.0 (3.0–7.1)	0.088
Nonclassical monocytes‡	9.6 (5.5–12.1)	8.8 (6.3–11.6)	0.900

Notes:

§ Mann–Whitney U test;

† percentage of total leukocytes;

‡ percentage of total monocytes.

Abbreviation: AMD, age-related macular degeneration.

Table 3 Recruitment molecules on subpopulation of monocytes, expressed as median percentage positive for marker (interquartile range)

Cell population	Marker	Patients with AMD	Control individuals	P-value§
Classical monocytes	CD11a	100 (100–100)	100 (100–100)	1.000
	CD11b	98.6 (94.6–99.9)	99.4 (95.1–99.9)	0.432
	CD62L	19.2 (3.6–53.5)	19.4 (6.0–70.3)	0.501
	CD54	99.5 (97.8–99.8)	99.5 (98.5–99.8)	0.896
	CD162	100 (100–100)	100 (100–100)	1.000
Intermediate monocytes	CD11a	100 (100–100)	100 (100–100)	0.317
	CD11b	99.4 (97.7–100)	100 (99.5–100)	0.032
	CD62L	15.9 (8.7–34.7)	13.0 (5.1–42.6)	0.971
	CD54	100 (99.2–100)	99.9 (99.4–100)	0.871
	CD162	100 (100–100)	100 (100–100)	0.325
Nonclassical monocytes	CD11a	100 (100–100)	100 (100–100)	0.317
	CD11b	41.9 (34.9–54.3)	48.0 (32.9–58.5)	0.363
	CD62L	1.6 (0.9–3.0)	5.0 (0.9–8.6)	0.152
	CD54	98.8 (98.1–99.6)	98.8 (97.2–99.3)	0.773
	CD162	100 (100–100)	100 (100–100)	0.309

Note:

§ Mann–Whitney U test. Bold values are statistically significant.

Abbreviations: AMD, age-related macular degeneration; CD, cluster of differentiation.

Table 4 B-lymphocytes and subgroups, expressed as median percentage (interquartile range)

Population of cells	Patients with AMD	Control individuals	P-value§
Total B-lymphocytes†	6.7 (4.9–9.8)	6.1 (4.5–9.7)	0.603
Memory B-lymphocytes‡	13.4 (7.9–27.3)	18.6 (12.2–26.0)	0.327
Naïve B-lymphocytes‡	65.3 (49.9–77.9)	58.7 (52.1–70.4)	0.367
Regulatory B-lymphocytes‡	50.7 (41.7–68.1)	45.6 (36.5–58.4)	0.103
Aging B-lymphocytes‡	1.0 (0.4–1.8)	1.5 (0.8–3.5)	0.132

Notes:

§ Mann–Whitney U test;

† percentage of total lymphocytes;

‡ percentage of total B-lymphocytes.

Abbreviation: AMD, age-related macular degeneration.